Shares of Boston Scientific Corp. BSX rallied 1.9% in premarket trading Thursday, after the medical technology company beat expectations for both profit and sales, amid strength in its cardiovascular business, and raised its full-year outlook. Net income rose to $261 million, or 18 cents a share, from $246 million, or 17 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of 53 cents beat the FactSet consensus of 49 cents. Sales grew 11.0% to $3.
9% in premarket trading Thursday, after the medical technology company beat expectations for both profit and sales, amid strength in its cardiovascular business, and raised its full-year outlook. Net income rose to $261 million, or 18 cents a share, from $246 million, or 17 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of 53 cents beat the FactSet consensus of 49 cents. Sales grew 11.0% to $3.60 billion, above the FactSet consensus of $3.